Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis
Sponsor: Muhammad Aamir Latif
Summary
The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard anticoagulant in the treatment of cerebrosinovenous thrombosis (CSVT).
Official title: To Determine the Safety and Efficacy of Oral Rivaroxaban and Standard Anticoagulant in the Treatment of Cerebrosinovenous Thrombosis in Children
Key Details
Gender
All
Age Range
2 Months - 18 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2023-12-01
Completion Date
2025-12-31
Last Updated
2026-04-13
Healthy Volunteers
No
Conditions
Interventions
Rivaroxaban
Children were treated initially with low molecular weight heparin (LMWH) for 7 to 10 days followed by oral rivaroxaban for 3 months.
Warfarin
Children received initially low molecular weight heparin (LMWH) for 7 to 10 days followed by oral warfarin for 3 months.
Locations (1)
The Children's Hospital
Lahore, Punjab Province, Pakistan